Diabetes Mellitus, Type 2 Clinical Trial
— SURE GERMANYOfficial title:
A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes
Verified date | March 2023 |
Source | Novo Nordisk A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months. The participants will be asked to complete some questionnaires about their health and their diabetes treatment. Participants will complete these during their normally scheduled visits with their study doctor.
Status | Completed |
Enrollment | 789 |
Est. completion date | May 25, 2021 |
Est. primary completion date | May 25, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - - Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol) - The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative and the treating physician before and independently from the decision to include the patient in this study - Male or female, age 18 years or older at the time of signing informed consent - Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion - Available and documented haemoglobin A1c (HbA1c) value equal to or below 12 weeks prior to initiation of semaglutide treatment Exclusion Criteria: - - Previous participation in this study. Participation is defined as having given informed consent in this study - Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation - Treatment with any investigational drug within 90 days prior to enrolment into the study - Hypersensitivity to semaglutide or to any of the excipients |
Country | Name | City | State |
---|---|---|---|
Germany | Novo Nordisk Investigational Site | Amberg | |
Germany | Novo Nordisk Investigational Site | Aschaffenburg | |
Germany | Novo Nordisk Investigational Site | Augsburg | |
Germany | Novo Nordisk Investigational Site | Bad Mergentheim | |
Germany | Novo Nordisk Investigational Site | Bad Oeynhausen | |
Germany | Novo Nordisk Investigational Site | Bautzen | |
Germany | Novo Nordisk Investigational Site | Berlin | |
Germany | Novo Nordisk Investigational Site | Berlin | |
Germany | Novo Nordisk Investigational Site | Berlin | |
Germany | Novo Nordisk Investigational Site | Berlin | |
Germany | Novo Nordisk Investigational Site | Berlin | |
Germany | Novo Nordisk Investigational Site | Bernau bei Berlin | |
Germany | Novo Nordisk Investigational Site | Bonn | |
Germany | Novo Nordisk Investigational Site | Bramsche | |
Germany | Novo Nordisk Investigational Site | Darmstadt | |
Germany | Novo Nordisk Investigational Site | Dessau-Roßlau | |
Germany | Novo Nordisk Investigational Site | Dresden | |
Germany | Novo Nordisk Investigational Site | Dresden | |
Germany | Novo Nordisk Investigational Site | Duisburg | |
Germany | Novo Nordisk Investigational Site | Eisenach | |
Germany | Novo Nordisk Investigational Site | Elsterwerda | |
Germany | Novo Nordisk Investigational Site | Erdmannhausen | |
Germany | Novo Nordisk Investigational Site | Erlangen | |
Germany | Novo Nordisk Investigational Site | Essen | |
Germany | Novo Nordisk Investigational Site | Essen | |
Germany | Novo Nordisk Investigational Site | Forst (Lausitz) | |
Germany | Novo Nordisk Investigational Site | Freisen | |
Germany | Novo Nordisk Investigational Site | Friedrichsthal | |
Germany | Novo Nordisk Investigational Site | Fulda | |
Germany | Novo Nordisk Investigational Site | Gebhardshain | |
Germany | Novo Nordisk Investigational Site | Gelnhausen | |
Germany | Novo Nordisk Investigational Site | Grasleben | |
Germany | Novo Nordisk Investigational Site | Großröhrsdorf | |
Germany | Novo Nordisk Investigational Site | Grünstadt | |
Germany | Novo Nordisk Investigational Site | Hainburg | |
Germany | Novo Nordisk Investigational Site | Halle (Saale) | |
Germany | Novo Nordisk Investigational Site | Hamburg | |
Germany | Novo Nordisk Investigational Site | Hammelburg | |
Germany | Novo Nordisk Investigational Site | Hannover | |
Germany | Novo Nordisk Investigational Site | Heidenheim an der Brenz | |
Germany | Novo Nordisk Investigational Site | Herrenberg | |
Germany | Novo Nordisk Investigational Site | Hof | |
Germany | Novo Nordisk Investigational Site | Hohenmölsen | |
Germany | Novo Nordisk Investigational Site | Jena | |
Germany | Novo Nordisk Investigational Site | Kempten (Allgäu) | |
Germany | Novo Nordisk Investigational Site | Köln | |
Germany | Novo Nordisk Investigational Site | Köln | |
Germany | Novo Nordisk Investigational Site | Leipzig | |
Germany | Novo Nordisk Investigational Site | Lichtenfels | |
Germany | Novo Nordisk Investigational Site | Lingen | |
Germany | Novo Nordisk Investigational Site | Ludwigsburg | |
Germany | Novo Nordisk Investigational Site | Magdeburg | |
Germany | Novo Nordisk Investigational Site | Marburg | |
Germany | Novo Nordisk Investigational Site | Marburg | |
Germany | Novo Nordisk Investigational Site | Mayen | |
Germany | Novo Nordisk Investigational Site | Meckesheim | |
Germany | Novo Nordisk Investigational Site | Mössingen | |
Germany | Novo Nordisk Investigational Site | Mühldorf Am Inn | |
Germany | Novo Nordisk Investigational Site | Mülheim | |
Germany | Novo Nordisk Investigational Site | München | |
Germany | Novo Nordisk Investigational Site | München | |
Germany | Novo Nordisk Investigational Site | Münster | |
Germany | Novo Nordisk Investigational Site | Neustrelitz | |
Germany | Novo Nordisk Investigational Site | Nürnberg | |
Germany | Novo Nordisk Investigational Site | Oranienburg | |
Germany | Novo Nordisk Investigational Site | Osnabrück | |
Germany | Novo Nordisk Investigational Site | Otterbach | |
Germany | Novo Nordisk Investigational Site | Pohlheim | |
Germany | Novo Nordisk Investigational Site | Rellingen | |
Germany | Novo Nordisk Investigational Site | Rostock | |
Germany | Novo Nordisk Investigational Site | Saint Ingbert-Oberwürzbach | |
Germany | Novo Nordisk Investigational Site | Schönhausen (Elbe) | |
Germany | Novo Nordisk Investigational Site | Schorndorf | |
Germany | Novo Nordisk Investigational Site | Schwerin | |
Germany | Novo Nordisk Investigational Site | Seelow | |
Germany | Novo Nordisk Investigational Site | Soltau | |
Germany | Novo Nordisk Investigational Site | Sonsbeck | |
Germany | Novo Nordisk Investigational Site | Speyer | |
Germany | Novo Nordisk Investigational Site | Spremberg | |
Germany | Novo Nordisk Investigational Site | Stadtbergen | |
Germany | Novo Nordisk Investigational Site | Straubing | |
Germany | Novo Nordisk Investigational Site | Stuttgart | |
Germany | Novo Nordisk Investigational Site | Stuttgart | |
Germany | Novo Nordisk Investigational Site | Trier | |
Germany | Novo Nordisk Investigational Site | Ulm | |
Germany | Novo Nordisk Investigational Site | Viersen | |
Germany | Novo Nordisk Investigational Site | Villingen-Schwenningen | |
Germany | Novo Nordisk Investigational Site | Villingen-Schwenningen | |
Germany | Novo Nordisk Investigational Site | Wedemark | |
Germany | Novo Nordisk Investigational Site | Wetzlar | |
Germany | Novo Nordisk Investigational Site | Wiesloch | |
Germany | Novo Nordisk Investigational Site | Witzenhausen | |
Germany | Novo Nordisk Investigational Site | Wolmirstedt | |
Germany | Novo Nordisk Investigational Site | Wurzen | |
Germany | Novo Nordisk Investigational Site | Zwenkau |
Lead Sponsor | Collaborator |
---|---|
Novo Nordisk A/S |
Germany,
Vilsboll T, Lindahl CO, Nielsen NF, Tikkanen CK. Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes. Diabetes Obes Metab. 2023 Feb 21. doi: 10.1111/dom.15031. Online ahead of print. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Glycated Haemoglobin A1c (HbA1c) | Percent point | Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38) | |
Primary | Change in HbA1c | mmol/mol | Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38) | |
Secondary | Change in body weight (kg) | kg | Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38) | |
Secondary | Change in body weight (%) | Percent | Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38) | |
Secondary | Change in waist circumference | cm | Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38) | |
Secondary | HbA1c level below 8.0% (64 mmol/mol) (yes/no) | Number of participants | At end of study (week 28 to 38) | |
Secondary | HbA1c level below 7.5% (59 mmol/mol) (yes/no) | Number of participants | At end of study (week 28 to 38) | |
Secondary | HbA1c level below 7.0% (53 mmol/mol) (yes/no) | Number of participants | At end of study (week 28 to 38) | |
Secondary | Reduction in HbA1c of 1.0% point or more (yes/no) | Number of participants who achieved/not achieved reduction in HbA1c of 1.0% point or more | Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38) | |
Secondary | Weight reduction of 3.0% or more (yes/no) | Number of participants who achieved/not achieved weight reduction of 3.0% or more | Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38) | |
Secondary | Weight reduction of 5.0% or more (yes/no) | Number of participants who achieved/not achieved weight reduction of 5.0% or more | Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38) | |
Secondary | HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no) | Number of participants who achieved/not achieved HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more | Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38) | |
Secondary | Patient reported severe or documented hypoglycaemia (yes/no) | Count | Between baseline (week 0), end of study (week 28-38) | |
Secondary | Change in score for Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction | The status version (DTSQs) provides a measure of how satisfied patients are with their current diabetes treatment. It consists of 8 questions, which are to be answered on a Likert scale from 0 to 6 (0 = very dissatisfied to 6 = very satisfied). Six questions are summed to produce a total Treatment Satisfaction score. The remaining two questions are concerning perceived frequency of hyperglycaemia and perceived frequency of hypoglycaemia, respectively | Baseline (week 0), end of study (week 28 to 38) | |
Secondary | Change in score for Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction | The change version (DTSQc) has the same 8 items as the status version, but is reworded to direct the patients to compare the experience of the current treatment with the experience of previous treatment. Each question is scored on a scale of -3 to +3 (-3 = much less satisfied now to +3 = much more satisfied now), with 0 (midpoint), representing no change | Baseline (week 0), end of study (week 28 to 38) | |
Secondary | Change in score for Short Form (SF)-36 v2: Physical summary component | The SF-36®v2 questionnaire has 36 questions grouped into eight domains termed: physical functioning, bodily pain, role-physical, general health, vitality, social functioning, role-emotional and mental health, which again can be combined to give two summary component scores (overall mental- and physical health). | Baseline (week 0), end of study (week 28 to 38) | |
Secondary | Change in score for SF-36 v2: Mental summary component | The SF-36®v2 questionnaire has 36 questions grouped into eight domains termed: physical functioning, bodily pain, role-physical, general health, vitality, social functioning, role-emotional and mental health, which again can be combined to give two summary component scores (overall mental- and physical health). | Baseline (week 0), end of study (week 28 to 38) | |
Secondary | Patient completed the study under treatment with semaglutide (yes/no) | Count | At end of study (week 28 to 38) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |